Goserelin Acetate Drug Asset Due Diligence Report 2026

This Goserelin Acetate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

341

Registered trials

122

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Goserelin Acetate can convert its Synthetic peptide profile and GnRHR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Goserelin Acetate (query alias: goserelin)
Modality / target	Synthetic peptide; GnRHR; GnRHR agonists
Highest global status	Approved
Originator	AstraZeneca PLC
Active developers	Mithra Pharmaceuticals SA, AstraZeneca PLC, Shandong Luye Pharmaceutical Co., Ltd.

The MCP disease footprint includes Estrogen receptor positive breast cancer, Metrorrhagia, Uterine Hemorrhage. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCTs031260249	Phase 2	募集前	132	無増悪生存期間（PFS）：主たる解析対象集団を対象とし、無作為化日からPD又は理由を問わない死亡日のうち早い方までの期間とする。効果判定は、Response Evaluation Criteria in Solid Tumors （RECIST） Ver.1.1に準じて評価する。
ChiCTR2600126436	Phase 2	Not yet recruiting	48	RCB Index and Classification
NCT07552506	Not Applicable	Not yet recruiting	132	Menstrual recovery rate six months after transplantation

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Neoadjuvant androgen receptor pathway inhibition for patients with high-risk localized prostate cancer: 5-year survival update and PSMA PET correlatives of the randomized NeoPRO trial.

Phase 2; n=62; evaluation: Negative. Reported fields: BFS(5-year) = 35.0 % ; BFS(5-year) = 48.0 %

Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis.

Phase 3; n=184; evaluation: Positive. Reported fields: mPFS = 11.1 month ( 7.4 - 14.6); mPFS = 24.4 month ( 13.1 - 32.4)

A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer

Phase 2; n=25; evaluation: not stated. Reported fields: TTF(Median) = 17.0 months (95% Confidence Interval, 13.1 - 21.7); -; TTF(Median) = 42.1 months (95% Confidence Interval, 2.5 - NA)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Goserelin Acetate addresses Estrogen receptor positive breast cancer, Metrorrhagia, Uterine Hemorrhage. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2017-02-20	AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada	Approved	US$250.0M upfront; US$70.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Goserelin implant dosing regimens for improved patient compliance”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO